Keppra News
UCB says net profit fell 59 percent - International Herald Tribune
Sales of UCB's anti-epileptic drug Keppra, the company's main product, rose 35 percent to €1.0 billion (US$1.5 billion), UCB said in a statement. ...
UCB: Full Year 2007 Financial Results - PR-USA.net (press release)
Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing ...
UPDATE 1-UCB 2007 net hit by Schwarz buy, repeats outlook - Reuters
Growth was predominantly from epilepsy drug Keppra, with sales of more than 1 billion euros, while costs attached to the Schwarz merger and marketing ...
UCB 2007 Profit Declines on Schwarz Acquisition Costs (Update1) - Bloomberg
UCB bought Schwarz for $4.4 billion euros to gain new products as its two top-selling medicines, Keppra for epilepsy and Zyrtec for allergies, ...
UCB says net profit fell 59 percent - PR-Inside.com (Pressemitteilung)
Sales of UCB's anti-epileptic drug Keppra, the company's main product, rose 35 percent to ¤1.0 billion (US$1.5 billion), UCB said in a statement. ...
UCB FY EBITDA falls but at top end of forecast range; sees lower ... - Forbes
The company said its top line was driven by 'outstanding' sales of its Keppra drug, of more than 1 bln eur, supported by Xyzal sales, which reached 168 mln ...
Full Year 2007 Financial Results - PharmaLive.com (press release)
Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing ...
FDA Keppra Approval Good News for Children with Epilepsy - Fox Central Oregon
Friday's announcement concerning Food and Drug Administration (FDA) approval of Keppra (levetiracetam) as add- on therapy in treating partial-onset seizures ...
UCB: Full Year 2007 Financial Results - Web Services Journal
Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing ...
UCB: Full Year 2007 Financial Results - Web Services Journal
Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing ...
Keppra RSS Feed